Here's your US review and submission news in brief: The Vyondys 53 (golodirsen) saga took a surprising turn last week, as its sponsor Sarepta Therapeutics Inc.scored an approval for the Duchenne muscular dystrophy (DMD) drug from the US Food and Drug Administration after quietly appealing the complete response letter (CRL) from four months earlier.
The Center for Drug Evaluation and Research (CDER) has now approved
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?